Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
Номер патента: CA3198668A1
Опубликовано: 21-04-2022
Автор(ы): Devin Brent TESAR, Hubert Kettenberger, Peter Michael HUELSMANN, Rami Hannoush, Robert Franklin KELLEY, Jr., Shrenik Chetan MEHTA, Simon Theodor HANSEN, Stefan DENGL
Принадлежит: F Hoffmann La Roche AG, Genentech Inc
Опубликовано: 21-04-2022
Автор(ы): Devin Brent TESAR, Hubert Kettenberger, Peter Michael HUELSMANN, Rami Hannoush, Robert Franklin KELLEY, Jr., Shrenik Chetan MEHTA, Simon Theodor HANSEN, Stefan DENGL
Принадлежит: F Hoffmann La Roche AG, Genentech Inc
Реферат: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican. A therapeutic molecule targeted to a tissue in a patient may comprise a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican that are bound to (i.e., pre-complexed with) hyaluronic acid. Methods of delivery for a therapeutic molecule targeted to a tissue in a patient comprise administering any therapeutic molecule described herein to the patient and allowing the therapeutic molecule to provide long-acting delivery of the therapeutically active agent to the target tissue.
Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
Номер патента: EP4228706A1. Автор: Hubert Kettenberger,Stefan DENGL,Peter Michael HUELSMANN,Rami Hannoush,Robert Franklin KELLEY, Jr.,Shrenik Chetan MEHTA,Devin Brent TESAR,Simon Theodor HANSEN. Владелец: F Hoffmann La Roche AG. Дата публикации: 2023-08-23.